Viewpoint

The stock-market debut at the end of July of Imperial College London’s tech-transfer office is the best news for academic reform in years.

Complying with the EU’s labyrinthine new REACH chemicals legislation was always going to be a tortuous process. For those who wait too long, it could be impossible.

Technology transfer is a sensitive and complex process. Changing one factor won’t provide the magic bullet, says Anna S. Nilsson, Science and Technology Attaché at the Swedish Embassy in Washington DC.

It's better to have fewer, stronger, spin-offs than shoals of tiddlers, as Marina Murphy discovers.

Carlos Moreira, co-founder and chairman of Swiss data-encryption firm WISekey, talks to Science|Business editor Richard L. Hudson on the travails of entrepreneurship.

The international treaty on plant genetic resources needs a gesture of trust to repair the atmosphere of suspicion that has developed, argues Emile Frison from the International Plant Genetic Resources Institute.

The TeGenero drug trial is complete, and an ongoing study is examing whether trial requirements should be changed. But, asks Nuala Moran, should the trial ever have been approved?

EU technology policy is moving beyond the numbers game, and getting down to economic basics.

Without access to easy to use analysis tools, patents are becoming an expensive hindrance to many small companies, says Mick McLean, Head of Economics and Public Policy at Scientific Generics.

AstraZeneca’s outrageously high bid for Cambridge Antibody Technology underscores the heat rising in the biotech market.